In this episode, VibeCast host Ray Dogum speaks with Frank Gleeson, Co-Founder and CEO of Satellos Bioscience, about groundbreaking small molecule therapies for Duchenne muscular dystrophy.
Frank Gleeson’s journey into the world of small molecule therapy for Duchenne muscular dystrophy is a testament to the power of unexpected paths and unwavering determination. Growing up with modest beginnings, he never imagined his life taking a turn towards science and entrepreneurship. However, his relentless pursuit of knowledge and an innate talent for grasping new scientific concepts propelled him into a career that seamlessly merged business and scientific innovation. This unique blend of skills eventually led him to a pivotal discovery in the field of Duchenne muscular dystrophy, igniting a passion to make a meaningful impact in the lives of those affected by this devastating disease. Gleeson’s commitment to uncovering groundbreaking solutions has culminated in the formation of Satellos Bioscience, a company driven by the pursuit of a disease-modifying small molecule treatment that has the potential to revolutionize the landscape of Duchenne muscular dystrophy.
Key moments:
- 00:00:00 – Introducing Satellos Bioscience
- 00:03:26 – Stem Cells and Duchenne Muscular Dystrophy
- 00:09:15 – Potential Treatment for Duchenne Muscular Dystrophy
- 00:13:22 – Research Discovery and Company Formation
- 00:15:59 – Clinical Trial Planning and Future Development
- 00:17:33 – Company Inflection Points
- 00:19:08 – Drug Impact and Potential
- 00:20:10 – Potential Indications
- 00:22:38 – Funding and Financial Strategy
- 00:24:35 – Biotech Ecosystem and Growth
